Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease

Expert Opinion on Investigational Drugs

Volumn 16, Issue 5, 2007, Pages 563-567

  Husmann, Marc ^a   Barton, Matthias ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Anticoagulant therapy; Antiplatelet therapy; Dabigatran; Hemorrhage; Myocardial infarction; Stroke; Vascular disease; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ARGATROBAN; CLOPIDOGREL; COUMARIN; DABIGATRAN; DABIGATRAN ETEXILATE; DESULFATOHIRUDIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; RECOMBINANT HIRUDIN; SERINE PROTEINASE; THROMBIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY DISEASE; ARTERY THROMBOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD CLOTTING; BYPASS SURGERY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; EDITORIAL; FIBRIN FORMATION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LIMB ISCHEMIA; LONG TERM CARE; MONOTHERAPY; PROTEIN FUNCTION; RESTENOSIS; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; THROMBIN; THROMBOSIS; TREATMENT OUTCOME;

EID: 34248184152     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.5.563     Document Type: Editorial

References (28)

1. ROSENDAAL FR: Thrombosis in the young: epidemiology and risk factors: a focus on venous thrombosis. Thromb. Haemost. (1997) 78(1):1-6.
2. NORDSTROM M, LINDBLAD B, BERGQVIST D et al.: A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J. Intern. Med. (1992) 232(2):155-160.
3. ANDERSON FA Jr, WHEELER HB, GOLDBERG RJ et al.: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch. Intern. Med. (1991) 151(5):933-938.
4. AGNELLI G, CIMMINIELLO C, MENEGHETTI G et al.: Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events. J. Thromb. Haemost. (2006) 4(12):2599-2606.
5. ROTHWELL PM, COULL AJ, SILVER LE et al.: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet (2005) 366(9499):1773-1783.
6. CARO J, MIGLIACCIO-WALLE K, ISHAK KJ et al.: The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc. Disord. (2005) 5:14.
7. FUSTER V, BADIMON JJ, CHESEBRO JH: Atherothrombosis: mechanisms and clinical therapeutic approaches. Vasc. Med. (1998) 3(3):231-239.
8. VORCHHEIMER DA, BECKER R: Platelets in atherothrombosis. Mayo Clin. Proc. (2006) 81(1):59-68.
9. BECKER RC, BOVILL EG, SEGHATCHIAN MJ et al.: Pathobiology of thrombin in acute coronary syndromes. Am. Heart J. (1998) 136(4 Part 2 Suppl.):S19-S31.
10. FERINGA HH, VAN WANING VH, BAX JJ et al.: Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J. Am. Coll. Cardiol. (2006) 47(6):1182-1187.
11. FLAKER GC, GRUBER M, CONNOLLY SJ et al.: Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am. Heart J. (2006) 152(5):967-973.
12. BRAUNWALD E, ANTMAN EM, BEASLEY JW et al.: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J. Am. Coll. Cardiol. (2002) 40(7):1366-1374.
13. VAN DE WERF F, ARDISSINO D, BETRIU A et al.: Management of acute myocardial infarction in patients presenting with ST segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. (2003) 24(1):28-66.
14. STONE GW, MCLAURIN BT, COX DA et al.: Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. (2006) 355(21):2203-2216.
15. VENDROV AE, MADAMANCHI NR, HAKIM ZS et al.: Thrombin and NAD(P)H oxidase-mediated regulation of CD44 and BMP4-Id pathway in VSMC, restenosis, and atherosclerosis. Circ. Res. (2006) 98(10):1254-1263.
16. BEA F, KREUZER J, PREUSCH M et al.: Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arteriorcler. Thromb. Vasc. Biol. (2006) 26(12):2787-2792.
17. YUSUF S, ZHAO F, MEHTA SR et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. (2001) 345(7):494-502.
18. WAHLANDER K, ERIKSSON-LEPKOWSKA M, NYSTROM P et al.: Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Thromb. Haemost. (2006) 95(3):447-453.
19. ALBERS GW, DIENER HC, FRISON L et al.: Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 293(6):690-698.
20. OLSSON SB: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet (2003) 362(9397):1691-1698.
21. CHRISTERSSON C, OLDGREN J, BYLOCK A et al.: Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. J. Thromb. Haemost. (2005) 3(10):2245-2253.
22. WALLENTIN L, WILCOX RG, WEAVER WD et al.: Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet (2003) 362(9386):789-797.
23. HACKAM DG, EIKELBOOM JW: Antithrombotic therapy for peripheral arterial disease. Heart (2007) 93(3):303-308.
24. HACKAM DG, TAN MK, LIN PJ et al.: Supporting a call to action for peripheral artery disease: insights from two prospective clinical registries. J. Vasc. Surg. (2006) 44(4):776-781.
25. SCHULMAN S, LUNDSTROM T, WALANDER K et al.: Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study. Thromb. Haemost. (2005) 94(4):820-824.
26. HARENBERG J, JORG I, WEISS C: Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. Int. J. Toxicol. (2006) 25(3):165-169.
27. FIESSINGER JN, HUISMAN MV, DAVIDSON BL et al.: Ximelagatran versus low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA (2005) 293(6):681-689.
28. DOUKETIS JD, ARNEKLEV K, GOLDHABER SZ et al.: Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch. Intern. Med. (2006) 166(8):853-859.